Correction of haemorrhagic shock-associated coagulopathy and impaired haemostasis by plasma, prothrombin complex concentrates or an activated protein C-targeted DNA aptamer in mice

[1]  E. Pryzdial,et al.  Spotlight on animal models of acute traumatic coagulopathy: An update. , 2022, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[2]  G. Perkins,et al.  Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial , 2022, The Lancet. Haematology.

[3]  M. Cohen,et al.  An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice , 2021, Blood advances.

[4]  M. Sholzberg,et al.  Tranexamic acid evidence and controversies: An illustrated review , 2021, Research and practice in thrombosis and haemostasis.

[5]  A. Sauaia,et al.  Trauma-induced coagulopathy , 2021, Nature Reviews Disease Primers.

[6]  Ulrich Dirnagl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research* , 2020, BMC Veterinary Research.

[7]  Esther J Pearl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research , 2020, PLoS biology.

[8]  Review mechanisms , 2020 .

[9]  T. O’Keeffe,et al.  Review of massive transfusion protocols in the injured, bleeding patient. , 2019, Current opinion in critical care.

[10]  H. Ni,et al.  Prothrombin, alone or in complex concentrates or plasma, reduces bleeding in a mouse model of blood exchange-induced coagulopathy , 2019, Scientific Reports.

[11]  N. Adhikari,et al.  A regional massive hemorrhage protocol developed through a modified Delphi technique. , 2019, CMAJ open.

[12]  M. Schreiber,et al.  Barriers to clinical research in trauma , 2018, Transfusion.

[13]  H. Redl,et al.  Effect of Coagulation Factor Concentrates on Markers of Endothelial Cell Damage in Experimental Hemorrhagic Shock. , 2019, Shock.

[14]  C. Callaway,et al.  Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock , 2018, The New England journal of medicine.

[15]  James G. Chandler,et al.  Plasma-first resuscitation to treat haemorrhagic shock during emergency ground transportation in an urban area: a randomised trial , 2018, The Lancet.

[16]  Y. Ozier,et al.  A clinically relevant and bias-controlled murine model to study acute traumatic coagulopathy , 2018, Scientific Reports.

[17]  E. Wood,et al.  Massive transfusions for critical bleeding: is everything old new again? , 2018, Transfusion medicine.

[18]  Mark L. Johnson,et al.  Impact of tranexamic acid on coagulation and inflammation in murine models of traumatic brain injury and hemorrhage. , 2017, The Journal of surgical research.

[19]  S. Takach Lapner,et al.  Review of D‐dimer testing: Good, Bad, and Ugly , 2017, International journal of laboratory hematology.

[20]  C. Thiemermann,et al.  Activated Protein C Drives the Hyperfibrinolysis of Acute Traumatic Coagulopathy , 2017, Anesthesiology.

[21]  M. Bonab.  randomised trial , 2022 .

[22]  A. Tinmouth.  Assessing the Rationale and Effectiveness of Frozen Plasma Transfusions: An Evidence-based Review. , 2016, Hematology/oncology clinics of North America.

[23]  J. Vincent,et al.  The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition , 2016, Critical Care.

[24]  B. Cotton,et al.  Damage Control Resuscitation , 2016, Journal of intensive care medicine.

[25]  J. Holcomb,et al.  Modulating the endotheliopathy of trauma: Factor concentrate versus fresh frozen plasma , 2016, The journal of trauma and acute care surgery.

[26]  M. Dubick,et al.  Trauma-Induced Coagulopathy Is Associated with a Complex Inflammatory Response in the Rat , 2015, Shock.

[27]  H. Ni,et al.  The fibrinogen but not the Factor VIII content of transfused plasma determines its effectiveness at reducing bleeding in coagulopathic mice , 2015, Transfusion.

[28]  D. Hoyt,et al.  Hemorrhagic shock , 1997 .

[29]  David B Hoyt,et al.  Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. , 2015, JAMA.

[30]  B. Hunt.  Bleeding and coagulopathies in critical care. , 2014, The New England journal of medicine.

[31]  A. Perner,et al.  Low hemorrhage‐related mortality in trauma patients in a Level I trauma center employing transfusion packages and early thromboelastography‐directed hemostatic resuscitation with plasma and platelets , 2013, Transfusion.

[32]  E. Bulger,et al.  Clinical and mechanistic drivers of acute traumatic coagulopathy , 2013, The journal of trauma and acute care surgery.

[33]  C. Guerriero,et al.  The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. , 2013, Health technology assessment.

[34]  M. Crowther,et al.  Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate , 2012, Journal of thrombosis and haemostasis : JTH.

[35]  S. Stanworth,et al.  Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes , 2012, Journal of thrombosis and haemostasis : JTH.

[36]  M. Cohen,et al.  Animal models of trauma-induced coagulopathy. , 2012, Thrombosis research.

[37]  Nikolaos Scarmeas,et al.  The good, bad, and ugly? , 2012, Neurology.

[38]  C. Thiemermann,et al.  Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations , 2010, Journal of thrombosis and haemostasis : JTH.

[39]  G. Lippi,et al.  Prothrombin complex concentrates: an update. , 2010, Blood transfusion = Trasfusione del sangue.

[40]  J de Lange,et al.  An evidence-based review? , 2010, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[41]  M. Cohen,et al.  INCREASE IN ACTIVATED PROTEIN C MEDIATES ACUTE TRAUMATIC COAGULOPATHY IN MICE , 2009, Shock.

[42]  T. Madhusudhan,et al.  An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. , 2009, Chemistry & biology.

[43]  M. Parr,et al.  Traumatic coagulopathy: where are the good experimental models? , 2008, The Journal of trauma.

[44]  Kevin Mackway-Jones,et al.  The coagulopathy of trauma: a review of mechanisms. , 2008, The Journal of trauma.

[45]  A. Tefferi,et al.  How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. , 2007, Mayo Clinic proceedings.

[46]  E. Moore,et al.  Epidemiology of Urban Trauma Deaths: A Comprehensive Reassessment 10 Years Later , 2007, World Journal of Surgery.

[47]  Michael D Dalzell,et al.  Everything old is new again. , 2007, Biotechnology healthcare.

[48]  Gillian Murphy,et al.  Shedding of Syndecan-1 and -4 Ectodomains Is Regulated by Multiple Signaling Pathways and Mediated by a Timp-3–Sensitive Metalloproteinase , 2000, The Journal of cell biology.

[49]  C. Page,et al.  The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits , 1993, British journal of pharmacology.

[50]  J. Griffin,et al.  Physiologic inhibition of human activated protein C by alpha 1-antitrypsin. , 1988, The Journal of biological chemistry.

[51]  K. Johnson.  An Update. , 1984, Journal of food protection.

[52]  K. Yamamoto,et al.  Comparative studies on the serum levels of alpha-1-antitrypsin and alpha-macroglobulin in several mammals. , 1983, The Tohoku journal of experimental medicine.

[53]  J. C. Tressler,et al.  Fourth Edition , 2006 .

[54]  W. C.F.,et al.  Clinical and Experimental Investigations , 1936, Edinburgh medical journal.